<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-148653</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Treatment of apomorphine infusion adverse effects: subcutaneous nodules and neuropsychiatric complications</dc:title>
<dc:description xml:lang="en">Subcutaneous nodules and neuropsychiatric complications are the most relevant adverse effects during apomorphine infusion treatment. Subcutaneous nodules appear in almost all the patients and accurate information and training of both patient and caregiver is essential to minimise their impact on the treatment. Although neuropsychiatric complications are not more frequent than with other dopaminergic treatments, they are linked with increasing difficulty of treatment and worsening of patient&#146;s quality of life (AU)</dc:description>
<dc:creator>Giménez de Bejar, Verónica</dc:creator>
<dc:creator>Carballo Cordero, Manuel</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los nódulos subcutáneos y las complicaciones neuropsiquiátricas son los efectos adversos más relevantes durante el tratamiento con apomorfina en infusión. Los nódulos subcutáneos aparecen casi en la totalidad de los pacientes, y es imprescindible la correcta información y entrenamiento del paciente y su cuidador para minimizar su repercusión en el tratamiento. Las complicaciones neuropsiquiátricas, aunque no son más frecuentes que con otras terapias dopaminérgicas, se relacionan con una mayor dificultad de tratamiento y el empeoramiento de la calidad de vida del paciente (AU)</dc:description>
<dc:source>Rev Neurol;55(supl.1): s25-s29, 31 dic. 2012. tab</dc:source>
<dc:identifier>ibc-148653</dc:identifier>
<dc:title xml:lang="es">Tratamiento de los efectos adversos de la apomorfina en infusión: nódulos subcutáneos y complicaciones neuropsiquiátricas</dc:title>
<dc:subject>^d23948^s22073</dc:subject>
<dc:subject>^d29507</dc:subject>
<dc:subject>^d32276^s22079</dc:subject>
<dc:subject>^d10489^s22056</dc:subject>
<dc:subject>^d10489^s22057</dc:subject>
<dc:subject>^d982^s22020</dc:subject>
<dc:subject>^d6365^s22036</dc:subject>
<dc:subject>^d982^s22000</dc:subject>
<dc:subject>^d6365^s22057</dc:subject>
<dc:subject>^d12041^s22054</dc:subject>
<dc:subject>^d34371^s22036</dc:subject>
<dc:subject>^d12032^s22057</dc:subject>
<dc:subject>^d30931^s22054</dc:subject>
<dc:subject>^d18001</dc:subject>
<dc:subject>^d8771^s22054</dc:subject>
<dc:subject>^d3162</dc:subject>
<dc:subject>^d23948^s22020</dc:subject>
<dc:subject>^d53227</dc:subject>
<dc:subject>^d8771^s22036</dc:subject>
<dc:subject>^d14542^s22073</dc:subject>
<dc:subject>^d4258</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d2850^s22073</dc:subject>
<dc:subject>^d30931^s22067</dc:subject>
<dc:subject>^d34371^s22067</dc:subject>
<dc:subject>^d6365^s22027</dc:subject>
<dc:subject>^d12032^s22027</dc:subject>
<dc:subject>^d12041^s22027</dc:subject>
<dc:subject>^d30931^s22027</dc:subject>
<dc:subject>^d32276^s22000</dc:subject>
<dc:subject>^d32276^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>201212</dc:date>
</metadata>
</record>
</ibecs-document>
